ArticleJournal of experimental & clinical cancer research : CR2026
ZEB1 integrates stemness, differentiation blockade and immune suppression to orchestrate osteosarcoma aggressiveness.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundOsteosarcoma (OS) is a highly aggressive bone malignancy primarily affecting children and adolescents, with limited therapeutic options. The transcription factor ZEB1, a key regulator of epithelial-mesenchymal transition (EMT), promotes cancer stemness and tumor progression.
methodsWe investigated ZEB1 role in OS using genetic knockout and silencing in murine and patient-derived cellular OS models. Using in vitro functional assays, we assessed the effect of ZEB1 down-modulation on stemness (sarcosphere formation), anchorage-independent growth, chemotherapy sensitivity, and osteoblastic differentiation (osteogenic markers and matrix mineralization), while gene expression profiling provided hints on ZEB1 regulation of tumor cell transcriptional program. In vivo studies evaluated tumor growth and lung metastasis in ZEB1-deficient models, while ZEB1 restoration experiments mechanistically proved its role in OS aggressiveness.
resultsZEB1 loss in OS mouse models markedly reduced stemness-associated gene expression and functional sarcosphere formation, impaired anchorage-independent growth, and increased sensitivity to chemotherapy. Furthermore, ZEB1 inhibition restored osteoblastic differentiation capacity, evidenced by upregulation of osteogenic markers and matrix mineralization. In vivo, ZEB1 deletion in mouse OS cells significantly hindered tumor growth and lung metastasis, accompanied by increased tumor differentiation and decreased infiltration of pro-tumoral macrophages. Gene expression profiling revealed suppression of oncogenic pathways and inflammatory mediators upon ZEB1 loss, while restoration of ZEB1 rescued OS aggressive phenotype.
conclusionsOverall, our findings position ZEB1 as a critical driver of OS aggressiveness by regulating stemness, cellular differentiation, oncogenic signaling, and immune infiltration, and highlight differentiation-based therapeutic strategies as a promising avenue for osteosarcoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.